SANDCAT
Jan 23 2023
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)
Read MoreCapriCORN
Jan 23 2023
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
Read MoreRECORDATI MT8
Jan 23 2023
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
Read MoreIMVT TED
Jan 23 2023
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Read More
Lab-Grown Retinal Eye Cells Open Door For Clinical Trials to Treat Blindness
Jan 05 2023
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
Read More
UW Researcher Receives Grant to Expand Knowledge of Molecules Regulating Retinal Function
Dec 19 2022
Mrinalini Hoon, PhD, has been granted a $150,000 Research to Prevent Blindness (RPB) Career Advancement Award.
Read More
New Research May Shed Light on Impact of Toxic Metals on Aging Dogs
Dec 14 2022
New research led by a University of Wisconsin–Madison assistant professor could shed some light on whether toxic metals commonly found in and around the home could impact an older dog’s vision and overall health.
Read More
UW-Madison Launches New Ophthalmology Tissue Biobank
Nov 30 2022
The University of Wisconsin Department of Ophthalmology and Visual Sciences (DOVS) has entered into a new partnership aimed at systematically collecting, storing, processing and distributing human eye tissue for research purposes.
Read MoreIZOKIBEP (IL-17A)
Oct 07 2022
To assess the safety, tolerability, and immunogenicity of izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
Read More